Published in J Vasc Interv Radiol on October 01, 2008
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer (2012) 1.27
Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol (2013) 1.11
Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. J Magn Reson Imaging (2010) 0.94
Animal models of cancer in interventional radiology. Eur Radiol (2009) 0.92
Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors. ACS Nano (2013) 0.87
Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model. J Vasc Interv Radiol (2013) 0.84
Considerations for two inoculation methods of rabbit hepatic tumors: Pathology and image features. Exp Ther Med (2011) 0.84
Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma? Oncol Rev (2011) 0.83
The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res (2016) 0.81
Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol (2011) 0.80
An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. Infect Agent Cancer (2015) 0.78
Ultrasound-guided RNA interference targeting HIF-1 alpha improves the effects of transarterial chemoembolization in rat liver tumors. Onco Targets Ther (2015) 0.77
Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors. Onco Targets Ther (2015) 0.77
Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro. J Cancer Res Clin Oncol (2014) 0.77
Localized hyperthermia with iron oxide-doped yttrium microparticles: steps toward image-guided thermoradiotherapy in liver cancer. J Vasc Interv Radiol (2013) 0.77
Hepatic parenchymal changes following transcatheter embolization and chemoembolization in a rabbit tumor model. PLoS One (2013) 0.75
Relevance of Rabbit VX2 Tumor Model for Studies on Human Hepatocellular Carcinoma: A MicroRNA-Based Study. J Clin Med (2015) 0.75
Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Onco Targets Ther (2016) 0.75
Comparison of two different laparotomy methods for modeling rabbit VX2 hepatocarcinoma. World J Gastroenterol (2015) 0.75
Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. Cancers (Basel) (2012) 0.75
Preclinical Benefit of Hypoxia-Activated Intraarterial Therapy with Evofosfamide in Liver Cancer. Clin Cancer Res (2016) 0.75
Bone targeted bipolar cooled radiofrequency ablation in a VX-2 rabbit femoral carcinoma model. Clin Exp Metastasis (2015) 0.75
Hypoxia as a target for drug combination therapy of liver cancer. Anticancer Drugs (2017) 0.75
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol (1992) 11.03
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1998) 9.56
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Updated treatment approach to hepatocellular carcinoma. J Gastroenterol (2005) 3.43
Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J (2001) 2.51
Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol (2007) 1.83
Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol (2005) 1.36
Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol (2001) 1.30
Comparison of two different methods for inoculating VX2 tumors in rabbit livers and hind limbs. J Vasc Interv Radiol (2008) 1.29
A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol (2007) 1.23
Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) (2002) 1.13
Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol (2004) 1.12
Comparison of transcatheter intraarterial perfusion MR imaging and fluorescent microsphere perfusion measurements during transcatheter arterial embolization of rabbit liver tumors. J Vasc Interv Radiol (2007) 1.10
Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol (2007) 1.07
Hypoxia-inducible factor-1alpha expression in experimental cirrhosis: correlation with vascular endothelial growth factor expression and angiogenesis. APMIS (2007) 0.87
Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol (2004) 0.87
Partition of calibrated tris-acryl gelatin microspheres in the arterial vasculature of embolized nasopharyngeal angiofibromas and paragangliomas. J Vasc Interv Radiol (2005) 0.85
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys (2007) 3.65
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology (2012) 3.29
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
Dysplastic lesions in inflammatory bowel disease: molecular pathogenesis to morphology. Arch Pathol Lab Med (2013) 2.11
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology (2009) 2.02
Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis (2003) 1.98
Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr (2005) 1.97
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol (2008) 1.84
Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology (2014) 1.78
Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol (2007) 1.73
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol (2006) 1.68
Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol (2006) 1.64
Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol (2011) 1.64
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Transcatheter intraarterial therapies: rationale and overview. Radiology (2011) 1.59
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol (2005) 1.58
Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol (2005) 1.57
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology (2004) 1.57
Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology (2010) 1.57
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg (2013) 1.56
Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res (2010) 1.56
Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology (2010) 1.55
Complications of renal transplantation. Radiographics (2005) 1.55
Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol (2005) 1.54
Automated rectilinear self-gated cardiac cine imaging. Magn Reson Med (2004) 1.52
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol (2007) 1.51
Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys (2009) 1.51
Cutaneous thermal injury after endovenous laser ablation of the great saphenous vein. J Vasc Interv Radiol (2004) 1.50
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata. Cardiovasc Intervent Radiol (2004) 1.48
Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol (2013) 1.47
Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report. Surg Neurol (2005) 1.46
Optional or permanent: clinical factors that optimize inferior vena cava filter utilization. J Vasc Interv Radiol (2012) 1.46
Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic. J Vasc Interv Radiol (2010) 1.46